Speaker(s): 

Myla Deganich, DO, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Differentiate pseudoendocrine sarcoma from well‑differentiated neuroendocrine tumors and paraspinal paragangliomas, which are the most frequent sources of diagnostic confusion.

• Recognize the hallmark immunophenotypic feature of pseudoendocrine sarcoma—strong nuclear β‑catenin expression resulting from recurrent activating CTNNB1 point mutations.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Zachary Hoffer, MD PhD and Jeffrey Prichard, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.